Project Grant R44AI100753

Federal Grant Award Summary Mucommune LLC received a $310,136 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of August 21, 2025 and completion date of July 31, 2027. The award supports the development of an intravaginal ring (IVR) device engineered to release lactic acid for the treatment and prevention of bacterial vaginosis (BV). The project addresses a...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $2.3 million Project Grant to the University of California, Davis to fund research targeting CD4 T follicular helper cells for enhancing HIV vaccine-induced humoral immunity. The two-year award, issued on May 12, 2021 under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support preclinical studies in rhesus macaques to better understand the immunological mechanisms...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Weill Medical College of Cornell University a $4.69 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 25, 2025, for research spanning through August 31, 2029. This project will leverage a novel infant non-human primate model of breast milk transmission to identify and validate biomarkers that predict the efficacy of broadly neutralizing...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $381,487 to the University of Maryland, Baltimore (UMB) to assess the early implementation of long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) among adolescent girls and young women (AGYW) at high risk of HIV acquisition in Zambia. The key objectives are to: 1) Evaluate implementation determinants of CAB-LA...

Federal Cooperative Agreement Summary Weill Medical College of Cornell University received a $1,275,484 Cooperative Agreement from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 12, 2025, with a completion date of June 30, 2030. The research initiative, titled "An Early Life Multivalent Immunization Strategy for the Induction of Neutralization Breadth," focuses on developing an...

Federal Project Grant Award Summary Emory University received a $1,332,155 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded June 10, 2025, with a completion date of May 31, 2030. The grant supports systematic research to optimize broadly neutralizing antibody (BNAb) immunotherapies combined with antiretroviral therapy (ART) for HIV cure in infants with perinatal infection, with...

Federal Grant Award Summary Mucommune LLC received a $1,025,000 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on June 23, 2025, with a completion date of May 31, 2028. The award supports the development of MM-009, a lactic acid-releasing intravaginal ring (LA-IVR) designed to treat and prevent bacterial vaginosis (BV). The product is engineered to deliver lactic acid over a...

Federal Project Grant Award Summary Weill Medical College of Cornell University received a $4.63 million Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 1, 2025, with completion targeted for June 30, 2030. This award funds translational research to develop the BG505 germline-targeting HIV envelope SOSIP trimer as a safe and effective pediatric immunogen capable of eliciting...

Federal Grant Award Summary Siolta Therapeutics Inc. received a $529,498 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 5, 2025, through July 31, 2028. The award supports the development of STMC-105, a multispecies live biotherapeutic product (LBP) designed to prevent recurrent bacterial vaginosis (RBV) in women by restoring protective lactobacillus...

Grant Award Summary Duke University received a $791,661 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2030. The award supports research focused on developing an HIV-1 vaccine utilizing integrase-defective lentiviral vectors (IDLVs) to deliver HIV and SIV antigens. The research aims to optimize vaccine delivery platforms and multi-antigen strategies...